Trial reportInternational journal of cancer2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Open access · hybridAbstract readRandomized Controlled TrialAdaptive Clinical Trial
In one paragraph
Trial report in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
10.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer.Journal of comparative effectiveness research · 2026Pooled it
- Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.JAMA oncology · 2023Pooled it
- Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.Future oncology (London, England) · 2025Trial
- Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.Cancer medicine · 2024Trial
- Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.Targeted oncology · 2023Trial
- Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).International journal of cancer · 2022Trial
- Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.Prostate cancer and prostatic diseases · 2026Article
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Personalized intensification of treatment for hormone-sensitive prostate cancer.Nature reviews. Clinical oncology · 2026Review
- Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer.Oncology reviews · 2026Review
- Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.Scientific reports · 2025Article
- A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients.European journal of nuclear medicine and molecular imaging · 2025Article
- Recent advances in drug treatment for prostate cancer.Japanese journal of radiology · 2025Review
- Real‑world data on the outcomes of upfront docetaxel in hormone‑sensitive metastatic prostate cancer.Oncology letters · 2025Article
- Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer.Current oncology reports · 2025Review
- Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.Future oncology (London, England) · 2025Review
- Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review.Journal of bone oncology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
57 authors at 20 institutions in 2 countries.
Nicholas D JamesInstitute of Cancer Research, London, UK.ORCID 0000-0002-7314-8204
Noel W ClarkeThe Departments of Surgery & Urology, The Christie & Salford Royal Hospitals, Manchester, UK.ORCID 0000-0001-7776-8059
Adrian CookMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0003-4417-2632
Adnan AliThe Christie NHS Foundation Trust, Manchester, UK.ORCID 0000-0002-8344-3776
Alex P HoyleSalford Royal HS Foundation Trust, Manchester, UK.
Gerhardt AttardUCL Cancer Institute, University College London, London, UK.ORCID 0000-0002-4811-7983
Christopher D BrawleyMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0003-3641-278X
Simon ChowdhuryGuy's, King's, & St. Thomas' Hospitals, and Sarah Cannon Research Institute, London, UK.
William R CrossSt James University Hospital, Leeds, UK.ORCID 0000-0001-9276-3053
David P DearnaleyThe Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.ORCID 0000-0002-3954-2806
Johann S de BonoInstitute of Cancer Research, London, UK.ORCID 0000-0002-2034-595X
Carlos Diaz-MontanaMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0001-9082-4596
Duncan GilbertMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0003-1859-7012
Silke GillessenIstituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.ORCID 0000-0001-5746-6555
Clare GilsonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0001-6935-3232
Rob J JonesBeatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.ORCID 0000-0002-2904-6980
Ruth E LangleyMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0002-9706-016X
Zafar I MalikRadiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK.
David J MathesonSchool of Allied Health and Midwifery, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, WS1 3BD, UK.ORCID 0000-0002-3695-3167
Robin Millman(PPI) c/o MRC CTU at UCL, London, UK.
Chris C ParkerUro-Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
Cheryl PughMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0003-4584-9780
Hannah RushMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0001-9550-8808
J Martin RussellInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Dominik R BertholdCentre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.ORCID 0000-0002-1552-6617
Michelle L BucknerMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.
Malcolm D MasonCardiff University, School of Medicine, Cardiff, UK.ORCID 0000-0003-1505-2869
Alastair W S RitchieGloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Alison J BirtleRosemere Cancer Centre, Lancashire Teaching Hospitals & University of Manchester, University of Central Lancashire, Lancashire, UK.ORCID 0000-0002-2621-0909
Susannah J BrockUniversity Hospital Dorset, Bournemouth, UK.ORCID 0000-0002-7561-0052
Prantik DasDepartment of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.ORCID 0000-0003-2976-4410
Dan FordCity Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham, UK.
Joanna GalePortsmouth Hospitals University Trust, Portsmouth, UK.ORCID 0000-0002-0285-5737
Warren GrantGloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK.ORCID 0000-0002-9677-5198
Emma K GrayMusgrove Park Hospital, Taunton, UK.
Peter HoskinMount Vernon Cancer Centre, Northwood, UK.ORCID 0000-0001-8323-9567
Mohammad M KhanDepartment of Oncology Castle Hill Hospital, Hull, UK.
Caroline ManettaBrighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Neil J McPhailDepartment of Clinical Oncology, Raigmore Hospital, Inverness, UK.ORCID 0000-0002-1847-7953
Joe M O'SullivanPatrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.ORCID 0000-0001-6999-2739
Omi ParikhRosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK.ORCID 0000-0003-4181-7124
Carla PernaRoyal Surrey NHS Foundation Trust, Guildford, UK.ORCID 0000-0002-3035-2408
Carmel J PezaroSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0003-2471-5265
Andrew S ProtheroeOxford University Hospitals NHS Foundation Trust, Oxfordshire, UK.ORCID 0000-0001-9413-0575
Angus J RobinsonSussex Cancer Centre, Brighton, UK.ORCID 0000-0002-5961-2189
Sarah M RudmanGuys and St Thomas' NHS Foundation Trust, London, UK.
Denise J SheehanRoyal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Narayanan N SrihariShrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK.
Isabel SyndikusRadiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK.ORCID 0000-0001-5781-2067
Jacob S TanguayVelindre Cancer Centre, Cardiff, UK.ORCID 0000-0001-6741-8426
Carys W ThomasKent Oncology Centre, Maidstone, Kent, UK.
Salil VengalilUniversity Hospital North Midlands NHS Trust, Staffordshire, UK.
John WagstaffSwansea University and the South West UK Cancer Centre, Swansea, UK.ORCID 0000-0002-1140-5981
James P WylieThe Christie NHS Foundation Trust, Manchester, UK.
Mahesh K B ParmarMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0003-0166-1700
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.ORCID 0000-0002-9323-1371
STAMPEDE Trials Collaborative Group
MRC Clinical Trials Unit at UCL · GBBeatson West of Scotland Cancer Centre · GBClatterbridge Cancer Centre NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBInstitute of Cancer Research · GBLancashire Teaching Hospitals NHS Foundation Trust · GBRoyal Marsden NHS Foundation Trust · GBThe Christie NHS Foundation Trust · GBBournemouth University · GBBrighton and Sussex Medical School · GBCardiff University · GBCheltenham General Hospital · GBCRUK Lung Cancer Centre of Excellence · GBGloucestershire Hospitals NHS Foundation Trust · GBIstituto Oncologico della Svizzera ItalianaMaidstone Hospital · GBMount Vernon Cancer Centre · GBMusgrove Park Hospital · GBOxford University Hospitals NHS Trust · GBPortsmouth Hospitals NHS Trust · GB
Funding
Cancer Research UK 12518Cancer Research UK CRUK_A12459Medical Research Council MC_UU_00004/01Medical Research Council MC_UU_12023/25
Abstract
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10
Indexed as
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantAbiraterone AcetateAgedAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesHormonesHumansMalePrednisolonePrednisoneRetrospective StudiesTreatment OutcomeAbiraterone AcetateAndrogen AntagonistsHormonesPrednisolonePrednisoneabirateroneclinical trialhormone therapyphase IIIprostate cancerrandomised controlled trialsurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.